PRIME MEDICINE INC
PRMENASDAQTrading Snapshot
- Day Range
- $3.05 – $3.11
- 52-Week Range
- $2.67 – $6.94
- Volume
- $4.00B
- Avg Volume
- $5.24B
- Shares Outstanding
- 180.6M
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 137.6x
- EPS (TTM)
- $-1.09
- Dividend Yield
- —
- Dilution (1yr)
- +25.4%
Why Investors Own PRME
- ✓High-growth profile — revenue up -3.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 44% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PRIME MEDICINE INC
PRME
StockOtter · stockotter.spaceAbout PRIME MEDICINE INC
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Prime Medicine Gets FDA Green Light for Gene Editing Study
Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology firm developing one-time curative genetic therapies, announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application f
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine's liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected in 2027 --
Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Prime Drink Group Provides Bi-Weekly MCTO Status Report
MONTREAL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, August 14 and August 27, 2026, the Company voluntaril
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME
BlackRock Inc. acquired a new stake in shares of Prime Medicine, Inc. (NASDAQ: PRME) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional